Trial Profile

Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IM21 CAR-T Cells (Primary) ; Cyclophosphamide; Fludarabine
Indications Multiple myeloma
Focus Adverse reactions

Most Recent Events

28 Sep 2020 Planned End Date changed from 20 Dec 2020 to 20 Dec 2021.
28 Sep 2020 Planned primary completion date changed from 10 Oct 2020 to 10 Oct 2021.
22 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com